PublizoomAward notice Supplies
Suministro del medicamento exclusivo: Factor IX Recombinante-Eftrenonacog Alfa (ALPROLIX).
Notice published in Spanish. The AI analysis summarises it for you in your language.
- Public buyer
- Servicio Madrileño de Salud - Hospital Universitario La Paz
Madrid - Place of performance
- Madrid
- Amount awarded
- €861,120 excl. VAT
- Planned end of contract
- 1 June 2027
likely re-tender around December 2026 - Bids received
- 1
- Procedure
- Negotiated procedure without prior publication
The buyer consulted a few companies directly: it is no longer possible to take part. - Publication
- 10 September 2026
- Notice language
- Spanish
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Suministro del medicamento exclusivo: Factor IX Recombinante-Eftrenonacog Alfa (ALPROLIX).
Awarded to
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33600000
Winning prices for comparable contracts
- A quarter below
- €350,000
- Median
- €861,120
- A quarter above
- €2,267,877
Amounts awarded (excl. VAT) over the last 3 years for 257 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Suministro del medicamento exclusivo: Atogepant (AQUIPTA). Servicio Madrileño de Salud - Hospital Universitario La Paz · 1 October 2026 |
ABBVIE SPAIN, S.L.U. | €183,702 |
| Adquisición de medicamentos exclusivos: ublituximab (briumvi). Servicio Madrileño de Salud - Hospital Universitario La Paz · 1 October 2026 |
NEURAXPHARM SPAIN S.L. | €215,941 |
| Adquisición de medicamentos exclusivos: ramucirumab (cyramza). Servicio Madrileño de Salud - Hospital Universitario La Paz · 1 October 2026 |
Lilly S.A. | €252,236 |
| Suministro del medicamento exclusivo: Eptacog alfa (NOVOSEVEN). Servicio Madrileño de Salud - Hospital Universitario La Paz · 18 September 2026 |
NOVO NORDISK PHARMA, S.A. | €1,498,940 |
| Suministro del medicamento exclusivo: Givinostat (DUVYZAT). Servicio Madrileño de Salud - Hospital Universitario La Paz · 18 September 2026 |
ITALFARMACO, S.A | €1,235,071 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 623706-2026.